Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study

Figures & data

Table 1. Characteristics of patients with low (G1) and intermediate (G2) risk NMIBC in Sweden, 1997–2014.

	All patients	G1	G2	95% Cl (G1%)
Age at diagnosis (mean)	70.3	69.5	71.4
Gender, N (%)
Male	12,417 (75%)	6,676 (54%)	5,741 (46%)	52.9–54.6
Female	4,259 (25%)	2,604 (61%)	1,655 (39%)	59.7–62.6
Type of hospital, N (%)
University	5,139 (31%)	2,992 (58%)	2,147 (42%)	56.9–59.6
County	6,453 (39%)	3,703 (57%)	2,750 (43%)	56.2–58.6
District	5,084 (30%)	2,585 (50%)	2,499 (50%)	49.5–52.2
Healthcare region, N (%)
Stockholm/Gotland*	3,099 (19%)	2,127 (69%)	972 (31%)	67.0–70.3
Southern	3,283 (20%)	1,621 (49%)	1,662 (51%)	47.7–51.1
South-Eastern	1,931 (12%)	974 (50%)	957 (50%)	48.2–52.7
Uppsala/Örebro	3,393 (20%)	1,882 (56%)	1,511 (46%)	53.8–57.1
Western	3,423 (21%)	1,749 (51%)	1,674 (49%)	49.4–52.8
Northern	1,545 (9%)	926 (60%)	619 (40%)	57.5–62.4
Time periods, N (%)
1997–2002	4,933 (30%)	2,537 (51%)	2,396 (49%)	50.0–52.8
2003–2008	5,355 (32%)	2,998 (56%)	2,357 (44%)	54.7–57.3
2009–2014	6,388 (38%)	3,745 (59%)	2,643 (41%)	57.4–59.8

*Different grading classification.

Table 2. Univariate and multivariate Cox regression analyses of rate of recurrence and bladder cancer death.

	Recurrence				Bladder cancer death
	Univariate (95% Cl)	p-value	Multivariate (95% Cl)	p-value	Univariate (95% Cl)	p-value	Multivariate (95% Cl)	p-value
Gender
Male	1	Ref.	1	Ref.	1	Ref.	1	Ref.
Female	0.93 (0.89–0.98)	0.004	0.97 (0.91–1.01)	0.152	0.73 (0.63–0.86)	<0.001	0.74 (0.62–0.87)	<0.001
Tumour grade
G1	1	Ref.	1	Ref.	1	Ref.	1	Ref.
G2	1.48 (1.42–1.55)	<0.001	1.46 (1.39–1.52)	<0.001	2.27 (1.98–2.62)	<0.001	2.10 (1.82–2.42)	<0.001
Type of hospital
University	1	Ref.	1	Ref.	1	Ref.	1	Ref.
County	1.09 (1.04–1.15)	0.001	1.14 (1.81–1.21)	<0.001	1.24 (1.05–1.47)	0.01	1.21 (1.01–1.44)	0.037
District	1.16 (1.10–1.23)	<0.001	1.11 (1.04–1.17)	0.001	1.20 (1.01–1.43)	0.039	1.20 (0.99–1.45)	0.060
Healthcare region
Stockholm/Gotland	1	Ref.	1	Ref.	1	Ref.	1	Ref.
Southern	1.12 (1.04–1.20)	0.002	1.01 (0.94–1.08)	0.808	0.96 (0.77–1.20)	0.726	0.80 (0.63–1.01)	0.057
South–Eastern	0.99 (0.92–1.08)	0.928	0.88 (0.81–0.96)	0.004	1.07 (0.83–1.38)	0.595	0.88 (0.68–1.13)	0.305
Uppsala/Örebro	1.06 (0.99–1.13)	0.113	0.95 (0.88–1.07)	0.135	1.12 (0.90–1.38)	0.309	0.90 (0.72–1.12)	0.358
Western	1.18 (1.10–1.26)	<0.001	1.08 (0.99–1.61)	0.067	0.95 (0.76–1.19)	0.650	0.72 (0.56–0.92)	0.009
Northern	1.03 (0.95–1.13)	0.449	0.93 (0.85–1.01)	0.088	1.19 (0.92–1.54)	0.188	0.98 (0.75–1.28)	0.870
Time periods
1997–2002	1	Ref.	1	Ref.	1	Ref.	1	Ref.
2003–2008	0.98 (0.93–1.03)	0.452	0.99 (0.94–1.03)	0.729	1.04 (0.89–1.21)	0.592	1.01 (0.86–1.17)	0.939
2009–2014	0.88 (0.84–0.93)	<0.001	0.89 (0.85–0.94)	0.000	0.93 (0.75–1.15)	0.505	0.93 (0.75–1.15)	0.522
Age at diagnosis
≤60 years	1	Ref.	1	Ref.	1	Ref.	1	Ref.
61–70 years	1.19 (1.11–1.26)	<0.001	1.18 (1.10–1.25)	<0.001	1.98 (1.45–2.69)	<0.001	1.88 (1.38–2.56)	<0.001
71–80 years	1.23 (1.16–1.31)	<0.001	1.12 (1.12–1.27)	<0.001	4.96 (3.75–6.57)	<0.001	4.57 (3.45–6.06)	<0.001
>80 years	1.18 (1.10–1.27)	<0.001	1.14 (1.06–1.23)	<0.001	13.39 (10.08–17.78)	<0.001	12.76 (9.59–16.97)	<0.001

Figure 1. Risk of recurrences for patients with low- and intermediate-risk stratified by time periods.

Figure 2. Risk of bladder cancer death for low- and intermediate-risk patients.